Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies.
Together with EFPIA members Sanofi, Novartis, MSD, Pfizer UCB Biopharma, AZ, Fujifilm Cellular Dynamics and a group of leading EU academic institutions, Biovista will work to identify novel mechanisms of neurotoxicity using historical data to inform the development of in vitro and in vivo models. Additionally, it will further develop its own AI-platform supporting the prediction of AEs and decision-support throughout the R&D process.
Information on the project is available at the project web site: https://neuroderisk.eu